Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT04485286
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Lung Cancer
  • Pancreas Cancer
  • Radiation Fibrosis
  • Radiation Induced Lung Injury

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • [68Ga]CBP8 — DRUG
    Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.

Study Details

The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.

Key Dates

Start date
Jul 19, 2020
Status verified
Feb 2026
Primary completion
May 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
72 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Lung Cancer or Pancreatic Cancer Subjects Undergoing Radiation Therapy
    Lung cancer or pancreatic cancer patients will receive \[68Ga\]CBP8 and undergo PET imaging 1) prior to radiation therapy and 2) 3-6 months after radiation therapy

Primary Outcome Measure

Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury. [ Time Frame: 3-6 Months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Michael Lanuti, MD
[email protected]
617-726-6751
Eric Abston, MD
[email protected]
920-286-3773
Michael Lanuti, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Massachusetts General Hospital· Boston, MA

Related Studies